Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, be...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/22/3591 |
| _version_ | 1827644832452968448 |
|---|---|
| author | Amy Xiao Oleg E. Akilov |
| author_facet | Amy Xiao Oleg E. Akilov |
| author_sort | Amy Xiao |
| collection | DOAJ |
| description | The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, being ideal candidates for targeted anti-CD47 therapies. The classes of current anti-CD47-SIRPα therapeutic molecules present in a large variety and include monoclonal antibodies against CD47 and SIRPα, bioengineered SIRPα proteins, miRNAs, and bispecific antibodies. We provided a detailed analysis of all available investigational drugs in a contest of cutaneous T-cell lymphoma. A combination of blockade of the CD47-SIRPα axis and secondary targets in the tumor microenvironment (TME) may improve the clinical efficacy of current immunotherapeutic approaches. We evaluated the possible combination and outlined the most promising one. |
| first_indexed | 2024-03-09T18:25:52Z |
| format | Article |
| id | doaj.art-e3638040bc67479c9cad8ffb9e2a7d01 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T18:25:52Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-e3638040bc67479c9cad8ffb9e2a7d012023-11-24T07:57:54ZengMDPI AGCells2073-44092022-11-011122359110.3390/cells11223591Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell LymphomaAmy Xiao0Oleg E. Akilov1University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USACutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA 15261, USAThe loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, being ideal candidates for targeted anti-CD47 therapies. The classes of current anti-CD47-SIRPα therapeutic molecules present in a large variety and include monoclonal antibodies against CD47 and SIRPα, bioengineered SIRPα proteins, miRNAs, and bispecific antibodies. We provided a detailed analysis of all available investigational drugs in a contest of cutaneous T-cell lymphoma. A combination of blockade of the CD47-SIRPα axis and secondary targets in the tumor microenvironment (TME) may improve the clinical efficacy of current immunotherapeutic approaches. We evaluated the possible combination and outlined the most promising one.https://www.mdpi.com/2073-4409/11/22/3591CD47SIRPαimmunotherapymycosis fungoidesSézary syndrome |
| spellingShingle | Amy Xiao Oleg E. Akilov Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma Cells CD47 SIRPα immunotherapy mycosis fungoides Sézary syndrome |
| title | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma |
| title_full | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma |
| title_fullStr | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma |
| title_full_unstemmed | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma |
| title_short | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma |
| title_sort | targeting the cd47 sirpα axis present therapies and the future for cutaneous t cell lymphoma |
| topic | CD47 SIRPα immunotherapy mycosis fungoides Sézary syndrome |
| url | https://www.mdpi.com/2073-4409/11/22/3591 |
| work_keys_str_mv | AT amyxiao targetingthecd47sirpaaxispresenttherapiesandthefutureforcutaneoustcelllymphoma AT olegeakilov targetingthecd47sirpaaxispresenttherapiesandthefutureforcutaneoustcelllymphoma |